Plovamer acetate(Plovamer acetate) - 药物靶点：HLA class II抗原_专利_临床

概要

基本信息

药物类型

聚合物

别名

Plovamer、Plovamer acetate (USAN)、CO-14

+ [1]

靶点

HLA class II抗原

作用方式

调节剂

作用机制

HLA class II抗原调节剂

治疗领域

免疫系统疾病神经系统疾病其他疾病+ [3]

在研适应症-

非在研适应症

克罗恩病复发-缓解型多发性硬化类风湿关节炎+ [1]

原研机构

Peptimmune, Inc.

在研机构-

非在研机构

权益机构

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C27H43N5O9

InChIKeyBBFYAJHFKUFNCR-GPOOOTPOSA-N

CAS号507277-44-3

Sequence Code 1058236825

来源: *****

关联

2

项与 Plovamer acetate 相关的临床试验

NCT01963611

/ Terminated临床2期

A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis

This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duration of 40 weeks.

开始日期2013-10-01

申办/合作机构

EMD Serono, Inc.

EUCTR2007-007759-15-HU

/ Completed临床2期

The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial

开始日期2008-11-10

申办/合作机构

Peptimmune, Inc.

100 项与 Plovamer acetate 相关的临床结果

登录后查看更多信息

100 项与 Plovamer acetate 相关的转化医学

登录后查看更多信息

100 项与 Plovamer acetate 相关的专利（医药）

登录后查看更多信息

1

项与 Plovamer acetate 相关的文献（医药）

2010-08-01·Journal of neuroimmunology3区 · 医学

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response

3区 · 医学

Article

作者: Augustyniak, M. ; Hittinger, T. ; Genova, M. ; Edan, G. ; Zanelli, E. ; Mascioli, E. ; Masci, A. ; Kovalchin, J. ; Kuca, B. ; Rimbert, M. ; Braudeau, C. ; Krieger, J. ; Patel, U. ; Collins, K.

PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-controlled, multiple-ascending dose, double-blind study was performed in patients with secondary-progressive MS. Treatment was given subcutaneously once weekly for 8 weeks, followed by a 4-week open-label treatment period with active drug. The most common adverse event was transient injection site reactions. Non-significant trend for increases in serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial T(H)2 immune response in subjects dosed with PI-2301 at 3 and 10 mg. MRI data indicated a non-significant trend for a reduction of lesion numbers in subjects treated with 1 and 3 mg PI-2301.

1

项与 Plovamer acetate 相关的新闻（医药）

2009-08-25

·BioSpace

Peptimmune, Inc. Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

100 项与 Plovamer acetate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09657	-	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发-缓解型多发性硬化	临床2期	法国	Peptimmune, Inc.	2010-02-03
克罗恩病	临床1期	美国	Peptimmune, Inc.	-
类风湿关节炎	临床1期	美国	Peptimmune, Inc.	-
葡萄膜炎	临床前	美国	Peptimmune, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01963611 (CTgov)	临床2期	复发-缓解型多发性硬化	255	Plovamer acetate (Plovamer Acetate 0.5 Milligram (mg))	遞遞膚鬱觸顧淵願憲製(顧艱鑰鹽願鹹願簾鏇願) = 壓壓範襯鹹觸醖醖鏇襯廠積遞憲憲憲鹽鑰膚遞 (選鏇夢憲繭鏇淵積鹹選, 2.93) 更多	-	2016-05-11
				Plovamer acetate 3 mg (Plovamer Acetate 3 mg)	遞遞膚鬱觸顧淵願憲製(顧艱鑰鹽願鹹願簾鏇願) = 網淵蓋選壓衊顧醖願齋廠積遞憲憲憲鹽鑰膚遞 (選鏇夢憲繭鏇淵積鹹選, 4.12) 更多